Welcome to our dedicated page for I-Mab news (Ticker: NBP), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect I-Mab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of I-Mab's position in the market.
NovaBridge (Nasdaq: NBP) said subsidiary Visara assigned its exclusive license for VIS-101 to Everest Medicines (HKEX: 1952) for development, manufacture and commercialization in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Everest will assume payment obligations under the assigned AskGene license and reimburse Visara for any upfront payment. VIS-101 is a bifunctional biologic targeting VEGF-A/ANG-2, completing a Phase 2 study in China and expected to be Phase-3-ready in 2026. NovaBridge also appointed Ian Woo, president and CFO of Everest Medicines, to its board.
The deal aims to leverage Everest’s regional clinical and commercialization expertise to accelerate VIS-101 development and patient access across Asia.
NovaBridge Biosciences (Nasdaq: NBP) announced it changed its corporate name from I‑Mab and will begin trading under the new ticker NBP at the open on October 30, 2025. Shareholder approval was granted on October 24, 2025 and no action is required by existing ADS holders. The company outlined a strategic shift to a global “hub‑and‑spoke” biotech platform, including a planned Hong Kong IPO and dual listings on Nasdaq and HKEX to broaden capital access.
Key program moves: the formation of subsidiary Visara and its acquisition of VIS‑101 (VEGF‑A/ANG2 bifunctional biologic); a ~$37M initial capital infusion into Visara; givastomig progressing toward a global randomized Phase 2 with first patient targeted in Q1 2026.
FAQ
What is the current stock price of I-Mab (NBP)?
